Document is current
Any future updates will be listed below
-
Authors
Meng, Sikun
Hara, Tomoaki
Sato, Tetsuya
Tatekawa, Shotaro
Arao, Yasuko
Saito, Yoshiko
Hirai, Toshiro
Motooka, Daisuke
Rennie, Sarah
Satoh, Taroh
Ogawa, Kazuhiko
Miura, Yutaka
Mori, Masaki
Doki, Yuichiro
Eguchi, Hidetoshi
Ishii, Hideshi
-
Funding
Funding for this research was provided by:
MEXT
Japan Agency for Medical Research and Development (JP23ym0126809, JP24ym0126809)
Suzuken Memorial Foundation (2024)
Uehara Memorial Foundation (2024)
Ministry of Education, Culture, Sports, Science and Technology (23K18313, 24K02518, 23KK0153, 24K22144, 23K19505, 24K19992, 25H01060)
Institute for Fermentation, Osaka (G2024-3-006)
- License Information
-
More Information
Article History
Received: 30 August 2025
Accepted: 29 November 2025
First Online: 10 December 2025
Declarations
:
: Partial institutional endowments were received from Hirotsu Bio Science Inc. (Tokyo, Japan), Kinshu-kai Medical Corporation (Osaka, Japan), Kyowa-kai Medical Corporation (Kawanishi, Hyogo and Osaka, Japan), IDEA Consultants Inc. (Tokyo, Japan), and Unitech Co. Ltd. (Chiba, Japan).
: All animals in this study were cared according to Osaka University’s standards for care and use of laboratory animals, and operation procedures were performed in accordance with protocols approved by the Laboratory Investigation Committee, Osaka University Medical School (Approval No. 04-105-014).All patient-derived tumor tissues used for PDX establishment were purchased from the Central Institute for Experimental Medicine and Life Science. The institute confirmed that all human samples were collected with informed consent from donors and with approval from the appropriate institutional ethics committee, in compliance with all relevant guidelines and regulations. No human participants were directly involved in this study.
